Angiotensin (1-7): Mechanistic, Biochemical, and Translational Benchmarks

Executive Summary: Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) is an endogenous heptapeptide hormone derived from the renin–angiotensin system that acts primarily as a Mas receptor agonist, counterbalancing the deleterious effects of angiotensin II (Oliveira et al., 2025). Its interaction with Mas modulates PI3K/AKT and ERK signaling pathways, which in turn regulate nitric oxide (NO), FOXO1, and COX-2 activity. Ang-(1-7) demonstrates potent anti-fibrotic and anti-inflammatory effects in pulmonary, hepatic, and renal models, and enhances glucose uptake, lipolysis, and insulin sensitivity (FexinidazoleSupply, 2024). The peptide offers neuroprotection in ischemic stroke and modulates reproductive and oncogenic processes. APExBIO provides Angiotensin (1-7) (A1041) with >99.7% purity, validated by HPLC and mass spectrometry, at https://www.apexbt.com/angiotensin-1-7.html.

Biological Rationale

Angiotensin (1-7) is a bioactive peptide generated from angiotensin I or II via endo- or carboxypeptidase cleavage steps (Oliveira et al., 2025). It is a central effector in the non-classical arm of the renin–angiotensin system (RAS). This system regulates cardiovascular, renal, and metabolic homeostasis. Unlike angiotensin II, Ang-(1-7) predominantly exerts protective, anti-fibrotic, and anti-inflammatory activities through the Mas receptor. Its primary sequence is Asp-Arg-Val-Tyr-Ile-His-Pro, mapping to residues 1–7 of angiotensin I (Figure 1). Ang-(1-7) is endogenously present in plasma and tissues and is upregulated during pathological states such as fibrosis, hypertension, and diabetes (TGF-b.com, 2023). This peptide’s stability and function make it a valuable research target for multi-system disease modeling.

Mechanism of Action of Angiotensin (1-7)

Angiotensin (1-7) binds specifically to the Mas receptor, a G protein-coupled receptor, activating downstream signaling cascades (Oliveira et al., 2025). The Mas receptor engagement modulates PI3K/AKT and ERK pathways. These pathways regulate the activity of nitric oxide synthase (NOS), FOXO1 transcription factor, and cyclo-oxygenase-2 (COX-2). The result is increased NO production, suppression of pro-fibrotic and pro-inflammatory genes, and inhibition of myofibroblast transition. Ang-(1-7) also influences metabolic regulators, increasing glucose uptake and stimulating lipolysis. It reduces insulin resistance, partly by downregulating inflammatory mediators and improving signaling through insulin pathways. Neuroprotective effects are mediated by anti-apoptotic signaling and reduced oxidative stress. In the reproductive system, Ang-(1-7) influences steroidogenesis and supports germ cell maturation. In cancer models, it inhibits angiogenesis and tumor cell proliferation via ERK and PI3K/AKT pathway modulation (Perospironekits, 2023; this article details mechanistic innovation and provides additional translational insight, while the current article highlights validated experimental benchmarks and workflow integration).

Evidence & Benchmarks

• Angiotensin (1-7) inhibits TGF-β-ERK-mediated myofibroblast transition in rat NRK-52E kidney cells at 100 nM with significant reduction in α-SMA expression (Oliveira et al., 2025, DOI).
• In vivo, Ang-(1-7) ameliorates dextran sulfate sodium-induced colitis in BALB/c mice at 0.01–0.06 mg/kg/day intraperitoneally, reducing histological damage and inflammatory cytokines (Oliveira et al., 2025, DOI).
• Ang-(1-7) increases glucose uptake and lipolysis in metabolic tissues and improves insulin sensitivity in animal models, with observed reductions in HOMA-IR index after 2 weeks of administration (TGF-b.com, internal link; this expands on novel metabolic endpoints, while the current article summarizes quantitative protocols and peptide handling parameters).
• High solubility in water (≥48.5 mg/mL) and DMSO (≥89.9 mg/mL), but insoluble in ethanol; purity >99.7% by HPLC and MS (APExBIO Certificate of Analysis, A1041 product page).
• Angiotensin (1-7) reduces ischemic brain injury in rodent models, decreasing infarct volume by 30–45% when administered at 0.5 mg/kg intraperitoneally pre-ischemia (Estragolesmallmol.com, internal link; this source covers emerging cerebroprotective research, while the current article provides validated dosing regimens and peptide quality parameters).

Applications, Limits & Misconceptions

Angiotensin (1-7) is widely used in preclinical models of fibrosis, inflammation, metabolic dysregulation, and neuroprotection. It also supports studies of reproductive function and cancer cell biology. As a Mas receptor agonist, its effects are context-dependent and may not replicate those of ACE inhibitors or AT1R antagonists. The peptide is not a direct antiviral agent, although angiotensin peptides influence viral spike protein binding (Oliveira et al., 2025). Its activity depends on receptor expression, tissue distribution, and enzyme-mediated stability.

Common Pitfalls or Misconceptions

• Angiotensin (1-7) is not a substitute for angiotensin II antagonists in hypertension management models.
• The peptide does not directly inhibit viral replication; its impact on SARS-CoV-2 is related to spike-receptor binding modulation, not viral clearance.
• Insufficient solubilization or improper storage (above -20°C, exposure to moisture) rapidly degrades peptide integrity.
• Effects require presence of functional Mas receptor; experiments in Mas-deficient systems may show no activity.
• Prolonged storage of working solutions (>48 hours) can result in hydrolysis and loss of bioactivity, especially at room temperature.

Workflow Integration & Parameters

APExBIO's Angiotensin (1-7) (A1041) is provided as a lyophilized solid, with recommended storage desiccated at -20°C. Reconstitution in water or DMSO is advised, with rapid dissolution at concentrations ≥48.5 mg/mL (water) or ≥89.9 mg/mL (DMSO). Standard in vitro working concentrations range from 10 nM to 1 μM; in vivo, typical dosing is 0.01–0.06 mg/kg/day (intraperitoneal), as validated in colitis and fibrosis models. Solutions should be freshly prepared and used within 24–48 hours to ensure maximal bioactivity. Quality is assured at >99.7% purity by HPLC/MS, supporting reproducibility in mechanistic and translational studies. For advanced protocols and translational guidance, see the related discussion in FexinidazoleSupply (2024), which details strategic protocol integration; this article adds experimental purity and peptide handling data not previously covered.

Conclusion & Outlook

Angiotensin (1-7) is a validated research tool for dissecting Mas receptor-mediated signaling and its systemic effects. Its anti-fibrotic, anti-inflammatory, metabolic, and neuroprotective properties are robustly supported by cellular and animal data. APExBIO’s A1041 product ensures batch-to-batch consistency and experimental reliability. As research expands into multi-system and translational domains, Ang-(1-7) is positioned as a key agent for modeling and modulating complex pathophysiological processes. For further mechanistic and translational insights, see Perospironekits (2023) and Estragolesmallmol.com (2023).